Flucinar (fluocinolon) gel 0.025% 15 g.


Manufacturer: Poland

Short-term local treatment of acute and severe non-infectious inflammatory skin diseases (dry forms), which are accompanied by persistent itching or hyperkeratosis and respond to treatment with glucocorticosteroids: seborrheic dermatitis, urticaria, atopic dermatitis, contact allergic eczema, erythema multiforme, lupus erythematosus, psoriasis of hair areas of the skin, advanced psoriasis, splashing lichen.



active substance: Fluocinolone

1 g of gel contains 0.25 mg of fluocinolone acetonide

Excipients: propylene glycol, ethanol 96%, sodium edetate, citric acid monohydrate, methylparaben (E 218), propylparaben (E 216), triethanolamine, carbomer, purified water.


colorless transparent gel with slight opalescence and the smell of ethyl alcohol.

ATX code D07A C04.



Fluocinolone acetonide is a highly active synthetic GCS for external use. When applied in the form of a gel at a concentration of 0.025%, it has a strong anti-inflammatory, antiallergic, antiallergic and vasoconstrictor effect. It has lipophilic properties and is easily absorbed through the skin. Already after applying 2 g of gel, the production of ACTH (ACTH) by the pituitary gland may decrease as a result of inhibition of the adrenal-pituitary gland system.

The mechanism of the anti-inflammatory action of fluocinolone acetonide is not fully understood, and it is believed that this agent reduces inflammatory processes by suppressing the production of prostaglandins and leukotrienes as a result of a decrease in the activity of phospholipase A2 and the release of arachoidonic acid from the phospholipids of the cell membrane. It has an antiallergic effect by suppressing the development of local hypersensitivity reactions. As a result of the local vasoconstrictor action, it reduces the risk of developing exudative reactions. Reduces protein synthesis and collagen deposition. Accelerates the breakdown of proteins in the skin and weakens proliferative processes.


Fluocinolone acetonide easily penetrates into the stratum corneum, where it gradually accumulates and is determined even 15 days after application. NOT metabolized in the skin. After absorption, it is systemically biotransformed mainly in the liver. It is excreted in the urine and in smaller quantities in the bile, mainly in the form of a compound with glucuronic acid, and also in small quantities unchanged.

The absorption of fluocinolone acetonide through the skin is enhanced when applied to sensitive skin in the anatomical folds of the body and face, as well as to skin with damaged epidermis or an existing inflammatory process. The use of an occlusive dressing causes an increase in the temperature and humidity of the skin, which also leads to an increase in the absorption of fluocinolone acetonide. In addition, absorption is enhanced with frequent use of the drug and on large areas of the skin. Absorption through the skin is higher in adolescents than in adults.

Short-term local treatment of acute and severe non-infectious inflammatory skin diseases (dry forms), which are accompanied by persistent itching or hyperkeratosis and respond to GCS treatment: seborrheic dermatitis, urticaria lichen, atopic dermatitis, contact allergic eczema, polymorphic erythema, lupus erythematosus, hair psoriasis , advanced psoriasis, lichen planus.

Pyoderma, chickenpox, herpes, actinomycosis, blastomycosis, sporotrichosis, numerous psoriatic plaques, cutaneous manifestations of syphilis, skin tuberculosis, erosive and ulcerative lesions of the gastrointestinal tract, wounds at the sites of applications, nevus, atheroma, melanoma, hemangioma, hemangioma skin tumors, skin cancer, rosacea and acne vulgaris, perianal and genital itching, perioral dermatitis, diaper dermatitis, thrombophlebitis and trophic ulcers against the background of varicose veins. Do not use after vaccination. Do not use the drug on large areas of the skin, especially on wounds that do not heal for a long time, for example, deep burn wounds. Do not use the drug in ophthalmology.